TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06773026: Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

Sponsor: Jerry Vockley, MD, PhD · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 24 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$6,407,600

Rescue Site Savings

+$4,216,400

Unlock Full NCT06773026 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06773026 Rescue Dossier →